

Resource Summary Report

Generated by [dkNET](#) on Sep 18, 2026

Anti-Human CD14 (RMO52)-148Nd

RRID:AB_2858228

Type: Antibody

Proper Citation

(Standard BioTools Cat# 3148010, RRID:AB_2858228)

Antibody Information

URL: http://antibodyregistry.org/AB_2858228

Proper Citation: (Standard BioTools Cat# 3148010, RRID:AB_2858228)

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Mass Cytometry

Antibody Name: Anti-Human CD14 (RMO52)-148Nd

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: RMO52

Antibody ID: AB_2858228

Vendor: Standard BioTools

Catalog Number: 3148010

Record Creation Time: 20260130T082141+0000

Record Last Update: 20260828T165516+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD14 (RMO52)-148Nd.

No alerts have been found for Anti-Human CD14 (RMO52)-148Nd.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Christenson ES, et al. (2025) Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(15), 3182.

Billon E, et al. (2025) BTN2A1 acquisition through trogocytosis enhances V α 9V β 2 T cell cytotoxicity against autologous and cancer cells. Cell reports, 44(10), 116387.

Yonemura A, et al. (2024) Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment. Cell reports, 43(1), 113613.